BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 2018;19:1903-14. [PMID: 30299993 DOI: 10.1080/14656566.2018.1531126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Jin D, Cui Z, Jin S, Zhou T, Guo B, Gao P, Li G. Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis. Front Pharmacol 2022;13:1096064. [PMID: 36699084 DOI: 10.3389/fphar.2022.1096064] [Reference Citation Analysis]
2 Huh Y, Cho YJ, Nam GE. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr 2022;31:17-27. [PMID: 35332111 DOI: 10.7570/jomes22021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 18.5] [Reference Citation Analysis]
4 Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice 2020;170:108487. [DOI: 10.1016/j.diabres.2020.108487] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
5 Mantovani A, Byrne C, Scorletti E, Mantzoros C, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & Metabolism 2020;46:427-41. [DOI: 10.1016/j.diabet.2019.12.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
6 Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr Vasc Pharmacol 2020;18:172-81. [PMID: 30961499 DOI: 10.2174/1570161117666190405164313] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
7 Mantovani A, Targher G, Zoppini G. Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. Clinics in Geriatric Medicine 2020;36:527-47. [DOI: 10.1016/j.cger.2020.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 13.5] [Reference Citation Analysis]
9 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol 2019;13:849-66. [PMID: 31353974 DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
10 Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, Du L, Mao S, Yin X, Lu Q. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother Res 2019;33:3140-52. [PMID: 31452288 DOI: 10.1002/ptr.6486] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 16.0] [Reference Citation Analysis]
11 Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? Angiology 2018;70:581-3. [DOI: 10.1177/0003319719848204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
12 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
13 Luo Z, Wu Q. Progress in Research on Nonalcoholic Fatty Liver and Gestational Diabetes. IJCM 2019;10:251-258. [DOI: 10.4236/ijcm.2019.104019] [Reference Citation Analysis]